A new research centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will look to exploit engineering approaches, involving a combination of stimulus-responsive nanocarriers and medical devices already in clinical use, to improve the therapeutic outcomes of drug-based cancer treatments. The centre will be based at the University of Oxford and has been made possible by a £10.1 million Programme Grant which includes £6.4 million from the Engineering and Physical Sciences Research Council (EPSRC). Led by Professors Coussios, Stride, Carlisle and Cleveland in the Institute of Biomedical Engineering, OxCD3 represents a partnership between the Department of Engineering Science, the Department of Oncology (Professors Seymour, Sibson and Vallis), the MRC Weatherall Institute of Molecular Medicine (Professor Rabbitts), the Nuffield Department of Surgical Science (Professor Friend) and the Clinical BioManufacturing Facility (Dr Moyle).
The CBF as part of the Jenner Institute recently won two Green Impact Bronze Awards.Green Impact is an environmental accreditation and awards scheme run by the National Union of Students, bringing staff and students together with their wider communities to enable and showcase positive changes in environmental practice. Winning the awards is proof ...
A clinical trial led by Prof Robert MacLaren (University of Oxford) successfully improved the vision of several patients with a genetic condition called choroideremia. The AAV vecored gene therapy product was imported and QP certified by the CBF. Choroideremia is relatively rare: it is thought to affect a thousand people in the UK. But Professor MacLaren believes that success with choroideremia demonstrates the principle that gene therapy could be used to cure other forms of genetic blindness including age-related macular degeneration. This condition causes blindness in 300,000 people in Britain and causes a deterioration in the vision of one in four people over the age of 75.
A Phase I trial has started at the University Hospital Birmingham to treat prostate cancer and the first patient has received AdNRGM on 23rd October. AdNRGM is a human adeno5 vector expressing nitroreductase, which cleaves an administered prodrug (CB1954) at the site of the tumour, generating the active toxic drug locally and thus reducing drug toxicity. The vector also contains GMCSF, which induces a strong immune response against cancer cells. It is expected that the combination of the immune response induced by the GMCSF and the activation of the prodrug C1954 operated by nitroreductase within the tumour tissue will result in the death of a significant number of prostate cancer cells.
The drug called lemtrada (also known as alemtuzumab or Campath-1H) was developed by Prof Herman Waldmann and Prof Geoff Hale at the Therapeutic Antibody Centre (TAC), which later became the CBF. Lemtrada is now made and marketed by Genzyme (Sanofi), and the drug has the potential to offer patients with multiple sclerosis a great improvement in their ability to function in their daily lives, as well as slower disease progression and fewer relapses.
The Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) marked its 10th anniversary on 13 September 2013. Many high profile guests from the University, the NHS, and key funding bodies were present at the symposium and reception, where Dame Sally Davies unveiled a plaque in honour of Prof Richard Moxon, who founded the centre. The CBF works closely with the CCVTM and supplied many vaccines for their clinical trials over the years. For an overview of all the clinical trials the CBF is involved in, please see the poster in the "Products & Clinical Trials" section.
The University of Oxford leads the world in Clinical, Pre-Clinical and Health subjects, for the third consecutive year, in the Times Higher Education World University Rankings subject tables.
The first issue of the Jenner Institute e-Newsletter was published in June 2013
The first patient to receive gene therapy for an incurable type of blindness was treated at the John Radcliffe Hospital as part of a trial led by Oxford University.
Almost one-third of the world’s population is infected with the bacterium that causes TB. Jenny Lunnon explains how the University’s Jenner Institute is developing vaccines to fight this and other infectious diseases. This article was first published in the University staff magazine, Blueprint, in October 2010.